On average, Max Planck Innovation closes 80 license agreements a year, about half of them with companies abroad. The nature and extent of the licenses are as varied as the payment modalities. They range from upfront payments and sales-based royalties to additional milestone payments, e.g. in the case of drug development. At present, several potential blockbusters are in development at our industry partners' sites.